Profile of Margetuximab: Evidence to Date in the Targeted Treatment of Metastatic HER2-positive Breast Cancer

Schlam, I; Nunes, R; Lynce, F

Lynce, F (通讯作者),Dana Farber Canc Inst, Breast Med Oncol, 450 Brookline Ave,Y12, Boston, MA 02115 USA.

ONCOTARGETS AND THERAPY, 2022; 15 (): 471

Abstract

Human epidermal growth factor receptor 2 (HER2) positive breast cancer accounts for about 20% of all breast cancers and this subtype has been historic......

Full Text Link